[Antithrombotic treatment in acute coronary syndrome].
Klinik für Kardiologie, Angiologie und Intensivmedizin, Vivantes Klinikum Neukölln, Berlin.
H
H
Darius
II. Med. Klinik, Innere Medizin/Kardiologie/Intensivmedizin, Rüsselsheim.
H-J
HJ
Rupprecht
Klinik für Innere Medizin 1, Katholisches Klinikum Mainz.
S
S
Genth-Zotz
Heidekreis-Klinikum Soltau.
T
T
Wittlinger
Kardiologie, Angiologie, Abteilung Innere Medizin III, Marienhausklinik Bitburg.
R
R
Zotz
D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D019983:Guideline Adherence; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D058921:Purinergic P2Y Receptor Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D015607:Stents
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D058921:Purinergic P2Y Receptor Antagonists